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The next generation of artificial vision devices (AVDs), which is currently developed in pre-clinical settings, has the
potential to improve the vision of blind patients with retinitis pigmentosa (RP) in a manner that they will be
categorized as visual impaired but no more as blind. This unprecedented vision improvement will result in a
mentionable quality of life gain which poses the question at which costs the next generation AVDs are to be
regarded as cost-effective, from a German healthcare payer perspective. In order to answer this research question
a Markov model was developed to simulate and to compare the costs and effects of next generation AVDs versus
best supportive care (BSC). Applying the base case settings resulted in incremental costs of €107,925, in 2.03
incremental quality-adjusted life years (QALYs) and in a cost-effectiveness ratio of €53,165 per QALY gained.
Probabilistic and deterministic sensitivity analyses as well as scenario analyses for the effect size and the AVD costs
were performed in order to investigate the robustness of results. In these scenario analyses a strong variation of the
cost-effectiveness results was obtained ranging from €23,512 (best case) to €176,958 (worst case) per QALY gained
by AVD therapy. This early health economic evaluation has to handle with three main uncertainty factors: the effect
size of next generation AVDs, the costs of next generation AVDs and the WTP threshold that might be applied in
RP patients, which reflect the main limitations of the presented assessment. In conclusion the presented early
cost-effectiveness evaluation has obtained that next generation AVDs have the potential to be a cost-effective
therapy option in patients with RP in Germany. The innovative nature, the high unmet medical need and the
expected unprecedented efficacy of next generation AVDs will highly likely lead to the case that even relatively
high incremental cost-effectiveness ratios, that have been obtained when simulating various effect and pricing
scenarios, will be regarded as acceptable from a German healthcare payer perspective.
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After almost half a century of research activities artificial
vision systems are moving in the clinical practice. These
devices are designed to provide prosthetic vision to the
blind by stimulating localized neural populations in one
of the retinotopically organized structures of the visual
pathway – typically the retina or visual cortex [1].
According to the World Health Organization (WHO)
blindness affects almost 45 million people worldwide
(≈300,000 in Germany [2]) and its prevalence constantlyCorrespondence: bjoern.schwander@ahead-net.de
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in any medium, provided the original work is pincreases along with population aging [3]. For some of
these diseases, there is currently no efficient treatment
for preventing severe visual loss or blindness. This is the
case for retinitis pigmentosa (RP) accounting for ≈ 1 mil-
lion patients worldwide [4] and for ≈ 20,000 patients in
Germany [5]. In RP, photoreceptor degeneration leads to
a progressive reduction of the visual field often declining
to legal blindness; in these patients prosthetic vision is
so far the only effective treatment strategy [4].
The current generation of these artificial vision devices
(AVDs) provides a level of prosthetic vision that allows RP
patients to perceive light, recognize shapes and objects and
even read large font print, which is already a substantialOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Overview of Markov health states and of the possible
state transitions for AVDs and BSC.
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mains still in a region that is defined as legal blindness
(best result 20/1260; legal blindness <20/200) [4,6,7].
Technological advancements, coupled with recent sci-
entific investigations, have transformed the focus of the
field from that of whether it is possible to create visual
sensations through electrical stimulation to the more
important question of how to optimize the perceptions
for maximum benefit [8]. The next generation of AVDs,
which is currently developed in pre-clinical settings, has
the future potential to improve the vision of blind pa-
tients in a manner that they will be categorized as visual
impaired but no more as blind (visual acuity >20/200)
[4]. This unprecedented vision improvement will result
in a mentionable quality of life gain which poses the
question at which costs the next generation AVDs are to
be regarded as cost-effective.
Accordingly the objective of the presented manuscript
is to determine at which effect size and at which cost
next generation AVDs will be regarded as cost-effective
when compared to the current practice (best supportive
care) for treating blind patients with RP from a German
healthcare payer perspective.
Methods
A Markov model with yearly cycles consisting of the
three health states ‘Blind’, ‘Visual Impaired’ and ‘Death’
was developed in Excel 2010 in order to simulate and to
compare the costs and effects of next generation AVDs
versus best supportive care (BSC). As there is currently
no cure for RP [5], BSC, consisting of all available
medical support for patients with RP (e.g. RP related
physician visits and rehabilitation, mobility training,
vision-enhancing equipment, visual aids etc.), was
selected as comparator.
Health state transition
As the development of these next generation AVDs is
currently in a pre-clinical stage, the actual treatment ef-
fect is not yet predictable and hence there is a high un-
certainty of treatment outcomes; therefore five different
AVD responder rate scenarios (proportion of patients
that obtain a vision improvement from ‘Blind’ to ‘Visual
Impaired’: 25%, 50%, 75%, 100% and 62.5% as average
base case) were applied in order to simulate the transi-
tion from the health states ‘Blind’ to ‘Visual Impaired’. It
was assumed that the responder rate of next generation
AVDs will be constant over time – hence it was simu-
lated that patients (responders) that have entered the
‘Visual Impaired’ state will either stay in this state or will
die. In case that the patients are treated with BSC it was
assumed that the vision cannot be restored (improved)
as blindness is currently a chronic (incurable) condition
for patients with advanced RP; hence patients treatedwith BSC cannot move from ‘Blind’ to ‘Visual Impaired’.
As there is currently no AVD long-term (end-of-life)
data available, not even for the first generation AVDs,
the transition from ‘Blind’ or ‘Visual’ Impaired’ to ‘Death’
was simulated on the basis of German life tables [9], ir-
respective of the therapy approach (AVD or BSC). For
the survival analyses a starting age of 51 years (SD
5.3 years) was simulated as this is the mean age for the
onset of bilateral blindness in RP [10].
The Markov health states (illustrated as bubbles) and
the possible state transitions (illustrated as arrows) for
the AVDs and BSC therapy approaches are shown in
Figure 1.
Cost measures
For the cost estimates a German healthcare payer per-
spective was applied. Yearly healthcare costs for the
health states ‘Blind’ and ‘Visual Impaired’ were deter-
mined on the basis of published literature [11,12]. Ac-
cording to Gruess et al. the annual direct vision related
healthcare costs are €3,163 for ‘Blind’ patients and
€2,845 for ‘Visual Impaired’ patients [11]. These costs
related to the reference year 2005 were inflated to 2014
values by applying an average yearly inflation rate of
2,9% (based on the average annual healthcare cost in-
crease of the German statutory health insurance from
2002 to 2012) [12]. Hence the annual costs in 2014
prices were estimated at €4,091 for ‘Blind’ patients and
at €3,680 for ‘Visual Impaired’ patients. The costs for
the health state ‘Death’ were set to zero. All these annual
health state costs were applied for both strategies inves-
tigated (AVD and BSC) as long as a patient stayed in the
related health state.
As the costs for the next generation AVDs are not yet
determined (released) different costing scenarios were
assumed using the cost of the currently available first-
generation device (Argus II® device) as basis [13]. These
costs are currently ranging from €70,000 to €100,000 in
the first year (which includes the costs for the device,
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nual follow-up costs are estimated at €1,500 in the sub-
sequent years (ongoing training and possible device
updates). As the costs for the next generation AVDs
could be lower (e.g. due to a more competitive environ-
ment) or higher (due to the expected improvement in ef-
ficacy) different AVD costing scenarios were analyzed:
the first year cost were set at €55,000, €70,000, €85,000
(mean base case), €100,000 and at €115,000 whereas the
annual follow-up costs were kept constant at €1,500.
For the BSC strategy it was assumed that the health
state costs for ‘Blind’ and ‘Visual Impaired’, determined
on the basis of published literature, already include all
relevant healthcare payer costs.
Effect measures
The effect estimates are based on published health re-
lated quality-of-life estimates for the health states ‘Blind’
and ‘Visual Impaired’. According to a recent NORC re-
port [14] the average health utility is 0.61 for the health
state ‘Blind’ (based on 6 publications with the following
utility values: 0.39, 0.51, 0.55, 0.60, 0.79 and 0.80), and
0.77 for ‘Visual Impaired’ (based on 8 publications with
the following utility values: 0.62, 0.65, 0.73, 0.76, 0.78,
0.79, 0.87 and 0.96); a health utility of zero was applied
for the state ‘Death’.
Discounting
Costs and effects were discounted by 3% per annum
according to German health economic recommenda-
tions (Institute for Quality and Efficiency in Healthcare
2009 [15]).
Sensitivity analyses
Probabilistic sensitivity analyses (by defining reasonable in-
put value distributions and running Monte-Carlo simula-
tions) and deterministic sensitivity analyses (by varying the
input value point estimates of the base case to reasonable
extreme values) were performed in order to investigate the
robustness of results. For both the cost and the effect in-
puts a normal distribution was estimated by applying a
standard deviation of 10% of the mean input value. For the
AVD responder rate as well as for first year AVD costs dif-
ferent scenario analyses were performed. A base case that
is defined by the mean value of the assumed scenarios for
the AVD responder rate and the first year AVD costs was
simulated in order to build the basis for performing the
deterministic sensitivity analyses. An overview of the input
values and the applied distributions for running the prob-
abilistic sensitivity analysis are shown in Table 1.
Model simulations, model outcome and time horizon
The model simulations are based on a Monte-Carlo simu-
lation process that uses 1,000 iterations (random numbergenerator scenarios) in order to investigate the variance of
results according to the applied input data distributions.
The results are provided as incremental cost-effectiveness
ratio that is expressed as the cost per quality-adjusted life
year (QALY) gained comparing next generation AVDs ver-
sus BSC from a German healthcare payer perspective.
Willigness-to-pay
As there is no official willingness-to-pay (WTP) threshold
for the cost per QALY gained in Germany the results of
the assessment were compared to other German cost per
QALY outcomes obtained in the field of visual interven-
tions using an overview provided Neubauer et al. 2010
[16] as basis. Furthermore the probability of whether
AVDs are a cost-effective at different WTP thresholds was
investigated by applying a cost-acceptability analysis.
Results
Base case analyses results
Comparing next generation AVDs versus BSC, while ap-
plying the base case settings (as described in Table 1),
resulted in mean incremental costs of €107,925, in 2.03
mean incremental QALYs and in a cost-effectiveness ra-
tio of €53,165 per QALY gained. The detailed results for
both therapy options, including the standard deviation
and the confidence intervals (based on the 1,000 itera-
tions), are provided in Table 2 below.
Probabilistic sensitivity analyses results
The fact that the simulations are based on a Monte-Carlo
simulation process (that uses 1,000 random number gener-
ator scenarios) enables to investigate the possible spread of
incremental cost-effectiveness ratio (ICER) estimates when
comparing AVD versus BSC. This result deviation is visu-
alized (for the base case setting) in form of an ICER plane
that shows the incremental effect (of comparing AVD vs
BSC) in QALYs on the x-axis and the incremental costs in
euros on the y-axis. This ICER plane is illustrated as a
cost-effectiveness scatterplot/isocontour in Figure 2. As it
can been seen in this figure most ICER estimates (darkest
areas) are located in the upper right corner of the ICER
plane which means that AVD is more effective but also
more costly compared to BSC and in this case the health-
care payers’ WTP for an additional QALY determines
whether AVD will be regarded as cost-effective or not.
Deterministic sensitivity analyses
The influence of single input parameters on the cost-
effectiveness analyses results was investigated by apply-
ing one-way sensitivity analyses on all relevant input
parameters. The results of this deterministic sensitivity
analyses are provided for the base case setting as
Tornado diagram in Figure 3.
Table 1 Overview of cost and effect input data applied in the model
Parameter Mean input value Standard deviation Distribution
Age at Therapy Start 51.1 5.3 Normal
Health State Costs ‘Visual Impaired’ €3,680 €368 Normal
Health State Costs ‘Blind’ €4,091 €409 Normal
Health State Costs ‘Death’ €0 €0 None
AVD Costs, first year (Base Case) €85,000 €8,500 Normal
AVD Costs, first year (Scenario 1) €55,000 €5,500 Normal
AVD Costs, first year (Scenario 2) €70,000 €7,000 Normal
AVD Costs, first year (Scenario 3) €100,000 €10,000 Normal
AVD Costs, first year (Scenario 4) €115,000 €11,500 Normal
AVD Costs, annual follow-up €1,500 €150 Normal
Health State Utility ‘Visual Impaired’ 0.77 0,077 Normal
Health State Utility ‘Blind’ 0.61 0.061 Normal
Health State Utility ‘Death’ 0 0 None
Responder Rate AVD (Base Case) 62.5% None None
Responder Rate AVD (Scenario 1) 25% None None
Responder Rate AVD (Scenario 2) 50% None None
Responder Rate AVD (Scenario 3) 75% None None
Responder Rate AVD (Scenario 4) 100% None None
Discounting of Costs 3% None None
Discounting of Effects 3% None None
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response rate (that will be further investigated in the
scenario analyses presented in the next subchapter)
showed the strongest impact on the cost-effectiveness
analyses results followed by the variation of the age atTable 2 Overview of the base case results comparing AVD
versus BSC
Costs in Euro AVD BSC Incremental
Mean Costs in Euro €189,887 €81,962 €107,925
Standard Deviation €16,732 €12,138 €15,035
2.5% Confidence Interval €155,538 €57,298 €77,379
97.5% Confidence Interval €221,407 €106,697 €136,992
Effect in QALYs AVD BSC Incremental
Mean QALYs 14.19 12.16 2.03
Standard Deviation 2.12 1.80 1.94
2.5% Confidence Interval 9.86 8.54 −1.70
97.5% Confidence Interval 18.48 15.66 5.87
Cost-Effectiveness Cost per QALY gained (AVD versus BSC)
Cost per QALY gained in Euro €53,165
Standard Deviation €13,273,467
2.5% Confidence Interval -€501,604
97.5% Confidence Interval €757,628
AVD Artificial Vision Device, BSC Best Supportive Care, QALY Quality Adjusted
Life Year.therapy start and variation of the observation time hori-
zon. Furthermore the variation of the health utility
values for the health states ‘Blind’ and ‘Visual Impaired’
and the variation of the annual follow-up costs of AVD
therapy were determined as parameters with a strong in-
fluence on the results, followed by cost and effect dis-
counting and by the costs of AVD in the first year
(which will also be part of the scenario analyses pre-
sented in the following). The possible impact of these
deterministic sensitivity analyses results on future health
economic evaluations will be outlined in the discussion
part.
Responder rate and AVD cost scenario analyses
The outcomes of the scenario analyses, on the AVD re-
sponder rate (RR) and on the first year AVD costs, are
presented in Table 3. In these analyses a strong variation
of the cost-effectiveness results was obtained ranging
from €23,512 (best case; RR 100%; AVD first year costs
€55,000) to €176,958 (worst case, RR 25%; €115,000) per
QALY gained by AVD therapy.
Interpretation of results
In Germany there is no official WTP threshold per
QALY gained in order to guide reimbursement decisions.
However, systematic comparisons of the cost-effectiveness
outcomes of a new intervention to the cost-effectiveness
Figure 2 Base case scatterplot/isocontour comparing AVD versus BSC.
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applied in the same disease area, are usually performed
[15]. Such systematic comparisons are usually based on
the efficacy frontier approach proposed by the German In-
stitute for Quality and Efficacy in Healthcare (IQWiG)
[17]. However for applying this efficacy frontier approach
there are specific preconditions to be fulfilled by the cost-
effectiveness assessments used as basis: they need to be
performed in the same country-setting and in the same
disease area, need to use that same efficacy outcome and
costing perspective, need to use a comparable comparator,
need to use a comparable treatment period and a compar-
able observation period [18]. For RP there is so far no Ger-
man cost-effectiveness study published but there are
studies published for age-related macular degeneration
(ARMD), hence there are at least studies available that are
related to the field of visual impairment/blindness.
Neubauer et al. investigated the cost-effectiveness of
ranibizumab compared to BSC [placebo; sham injection]
(in ARMD from a German healthcare payer perspective),
which resulted in costs per QALY gained ranging from
€13,505 (4 injections per year) to €87,862 (12 injections
per year – as applied in the underlying phase III trials)
[16]. In this paper further ARMD cost per QALY gainedFigure 3 Base case tornado diagram comparing AVD versus BSC. Comthresholds are provided whereas photodynamic therapy
compared to BSC ranged from €25,193 [19] to €46,535
[20] and pegaptanib versus BSC resulted in €54,252 [21]
per QALY gained.
These studies described above used a 2-year treatment
time horizon and an observation period of 10 years. Hence
beside the fact that these assessments are not performed
within the same disease area the different treatment time
and observation period do not allow an application of the
efficacy frontier approach. Thus it is currently not predict-
able which WTP thresholds German authorities might
apply for AVDs in RP. However considering these cost-
effectiveness ratios for ARMD therapies and considering
the high unmet medical need in blind RP patients (there is
currently no effective therapy) it is highly likely that a cost-
per QALY gained threshold of up to €80,000 will be con-
sidered as acceptable, as it is the case for ranibizumab in
ARMD. As this threshold cannot be verified, different
WTP thresholds (€40,000; €60,000 and €80,000) have been
applied in order to investigate the probability of whether
AVD is a cost-effective treatment strategy in RP when
compared to BSC.
In order to enable an interpretation of the various cost-
effectiveness outcomes of AMD versus BSC the scenarioment: ‘VIMP’ = ‘Visual Impaired’ State.
Table 3 Overview of the scenario analyses results
Outcome RR 25% RR 50% RR 62.5% RR 75% RR 100% Scenarios
IC (Euro) 81,640 78,606 77,674 76,658 75,237 AVD Cost €55,000
IE (QALYs) 0.80 1.59 2.03 2.41 3.20
ICER 102,050 49,438 38,263 31,808 23,512
IC (Euro) 96,276 94,752 92,826 91,983 90,158 AVD Cost €70,000
IE (QALYs) 0.80 1.59 2.03 2.41 3.20
ICER 120,345 59,592 45,727 38,167 28,174
IC (Euro) 110,984 109,218 107,925 106,731 104,685 AVD Cost €85,000
IE (QALYs) 0.80 1.59 2.03 2.41 3.20
ICER 138,730 68,691 53,165 44,287 32,714
IC (Euro) 126,384 123,346 122,218 121,913 119,396 AVD Cost €100,000
IE (QALYs) 0.80 1.59 2.03 2.41 3.20
ICER 157,980 77,576 60,206 50,586 37,311
IC (Euro) 141,566 139,301 138,746 137,416 134,948 AVD Cost €115,000
IE (QALYs) 0.80 1.59 2.03 2.41 3.20
ICER 176,958 87,611 68,348 57,019 42,171
RR Responder Rate, IC Incremental Costs in Euro, IE Incremental Effect in QALYs, ICER Incremental Cost-Effectiveness Ratio (Cost per QALY gained AVD vs BSC).
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Figure 4 in relation to different WTP thresholds.
Above it can be seen that 28% of the scenarios (7 of
25) are below a WTP threshold (per QALY gained) of
€40,000; that 60% of the scenarios (15 of 25) are below a
WTP threshold of €60,000 and that 76% of the scenarios
(19/25) are below a WTP threshold of €80,000.
Additionally three scenarios (best case, base case and
worst case) were selected in order to investigate the prob-
ability that AVDs (compared to BSC in RP) are a cost-
effective intervention in case of assuming different WTP
thresholds. This cost acceptability analyses are performed
on the basis of the probabilistic sensitivity analyses resultsFigure 4 Scenario analyses results in relation to different WTP thresh
rate and the Euro value defines the first year AVD costs in thousands (e.g. 2
of €55,000).(1,000 iterations) that are based on a Monte-Carlo simula-
tion process.
In Figure 5 it can be seen that the probability that AVD
is cost-effective is 0.07 (worst case), 0.36 (base Case) and
0.75 (best case) when considering a WTP threshold of
€40,000. Looking at a WTP threshold of €60,000 and
€80,000 the probability that AVD is cost-effective is 0.22
and 0.31 (worst case), 0.53 and 0.63 (base case) and 0.85
and 0.89 (best case), respectively.
Discussion
Early health economic evaluations differ from late-stage
evaluations (e.g. those used at the time of reimbursementolds. Scenario definition (labels): The percentage defines the responder
5%/€55 means AVD response rate of 25% and the first year AVD costs
Figure 5 Cost acceptability curves comparing AVD versus BSC. Scenario definition (labels): The percentage defines the responder rate and the
Euro value defines the first year AVD costs in thousands (e.g. 25%; €100 means AVD response rate of 25% and the first year AVD costs of €100,000).
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in that they are much more flexible and are designed to
explore uncertainty. This means they typically operate on
a less robust evidential basis than late-stage evaluations.
Also the presented early health economic evaluation of
the future potential of next generation AVDs for treating
blindness in Germany has to handle with three main un-
certainty factors: the effect size of next generation AVDs,
the costs of next generation AVDs and the WTP thresh-
old that might be applied in RP patients. These key
issues will be discussed in the following section in order
to define important considerations for future health eco-
nomic evaluations of AVDs (which are equivalents for
the limitations of the current modelling approach) and
to determine and conclude on the cost-effectiveness po-
tential of next generation AVDs. The discussion will be
completed by highlighting the current and the possible
future clinical health economic evidence requirements,
and thus the possible hurdles for obtaining statutory
reimbursement coverage, for next generation AVDs in
Germany.
Effect size and efficacy and safety
As the pre-clinical investigations for the next generation
AVDs are currently ongoing different efficacy scenarios
have been simulated. To simulate the efficacy of AVDs it
was assumed that the vision of a specific proportion of
patients (responders) improves in a manner that they
are no more categorized as blind (visual acuity >20/200)
which was then transferred into a quality of life im-
provement. Thus the current model does not take into
account a positive effect of minor vision improvements
(e.g. in non-responders) which might underestimate the
efficacy of AVDs. Once published clinical trial data on
next generation AVDs is available it will be possible to
apply an approach that takes into account the quality oflife impact of smaller vision improvements in order to
avoid an underestimation of the AVD efficacy.
The current modelling approach assumes that the vi-
sion improvement will be maintained over the patients’
lifetime. This procedure is based on the assumption that
the AVD implants (as well as the external parts) will
maintain its function over a lifetime period. Even in fu-
ture health economic evaluations it will be difficult to
eliminate this limitation as such long-term data on the
AVD function will not be available at the time of mar-
keting approval; such data may be available a long time
after marketing if the post-marketing surveillance works
well. In order to ensure at least a minimum functioning
period, AVD manufacturers should think about guaran-
teeing the function of AVDs over a specific time period.
Using such data it will be possible to simulate two sce-
narios: once assuming a lifetime function and the other
assuming that the AVD will work only for the guaran-
teed function period. Simulating a guaranteed function
period (shorter than lifetime) will increase the ICER esti-
mates, as it was seen in the one-way sensitivity analyses
on the observation period (10 years vs lifetime).
The current model does not take into account the pos-
sible impact of the safety profile of AVDs on the efficacy
(quality of life) as there is currently no safety data avail-
able for next generation AVDs. In order to restore the
vision in a manner that the patients’ vision improves
above the blindness threshold the next generation AVDs
need to enable a strongly increased resolution which will
highly likely be linked to more adverse effects. This is
based on the fact that achieving a higher resolution re-
quires that more electrodes need to implanted and that
these need to be set closer to each other which also affects
the amount of electrical power that can be delivered safely
to target neuronal tissue. Hence next generation AVDs will
operate near the natural charge/density limits which might
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sessments based on clinical trial outcomes should take into
account the influence of such adverse effects on the pa-
tients’ quality of life and should so enable to simulate the
safety profiles’ impact on the QALY estimates.
Furthermore a future modelling approach should
consider to base the cost-effectiveness outcomes not
only on QALY estimates but to use additional clinical
markers e.g. the visual acuity itself in order to express
cost-effectiveness differently. The rationale for this pro-
cedure is that the QALY approach is seen critical by
German authorities (especially by the IQWiG) and
hence using clinical markers, to provide additional cost-
effectiveness outcomes, will broaden the spectrum for
argumentation. Outcomes such as vision years gained
are commonly applied in visual impairment/blindness
cost-effectiveness assessment and performing such
analyses will hence enable a comparison of this cost-
effectiveness outcome to other studies in the field.
Pricing, healthcare costs and perspective
As there is currently no information available on the pos-
sible pricing of next generation AVDs, different pricing
scenarios have been simulated using the price of currently
available AVDs as basis. In order to present a wide range
of possible pricing scenarios these scenarios take into ac-
count prices that are higher and lower than the current
AVD costs. Although pricing scenarios assuming lower
AVD prices has been simulated it is highly likely that the
next generation AVDs will be more expensive that the
current generation, as the growing competition in this
market forces manufacturers to obtain the return of in-
vestment in a shorter period of time. Furthermore the an-
ticipated incremental efficacy delivers a good argument for
a price increase of next generation AVDs as such proced-
ure reflects a kind of value-based pricing approach (add-
itional money for an additional effect) that is already in
use for pharmaceuticals in Germany.
Another important aspect of AVD costing is the esti-
mation of annual follow-up costs that should reflect the
costs of ongoing training and monitoring, the costs of
possible device and software updates and the costs of
possible adverse effects. In the presented assessment
these costs were assumed at €1,500 which might conser-
vatively overestimate the annual follow-up costs of next
generation AVDs. Varying this estimate in one-way sen-
sitivity analyses obtained that the amount of follow-up
costs has a strong impact on the ICER and hence future
assessments should perform the estimation of follow-up
costs very accurately in order to avoid an over- or
underestimation of the follow-up effort and subsequently
of the ICER.
As requested by German health economic guidelines
[15] a healthcare payer perspective was applied in orderto estimate the cost-effectiveness of next generation AVDs.
However, focusing on the healthcare payer perspective
might underestimate the positive impact of a vision im-
provement. Lafuma et al. estimated the non-medical costs
of visual impairment in four European countries including
Germany and concluded that the “total non-medical costs
associated with visual impairment are considerable” and
that “hence the economics of visual impairment must be
considered from a societal perspective” [23]. Taking this
into account in combination with the issue, that next gen-
eration AVD prices will highly likely be located at the
upper limited applied in our analyses, future health eco-
nomic assessments should consider an additional investi-
gation of the societal perspective, which would broaden
the basis for the cost-effectiveness discussion on AVDs.
Willingness to pay threshold and deviation of results
As mentioned previously there is no official WTP thresh-
old per QALY gained in Germany. However, looking at the
outcomes of ARMD cost-effectiveness assessments the ef-
ficiency frontier approach might justify a WTP of around
€80,000 per QALY gained (please refer to the ‘Interpret-
ation of Results’ section). In light of the official WTP
thresholds in the United Kingdom that range between ≈
€24,000 and ≈ €36,000 (£20,000–£30,000) [24] this value
seems to be far too high to be acceptable. However, there
are other approaches e.g. that introduced by the WHO
that connect the WTP to the economic capacity of a coun-
try [25]. According to this WHO approach an intervention
is highly cost-effective if the ICER is less than the GDP per
capita and cost-effective if the ICER is between one and
three times the GDP per capita. Applying the German
GDP per capita (€30,484 in 2013) [26] the WHO WTP
threshold is ranging between ≈ €30,000 and ≈ €90,000
which is more in line with the WTP estimate based on the
ARMD cost-effectiveness studies. As the WTP threshold
cannot be predicted accurately different WTP thresholds
have been applied in order to investigate the probability of
whether AVD is a cost-effective treatment strategy in RP
when compared to BSC. In these analyses it was obtained
that there is a relatively high probability that next gener-
ation AVDs will be regarded as cost-effective intervention
if the WTP threshold is located at €80,000 with declining
probabilities if the WTP threshold is reduced.
Hence the cost-effectiveness of next generation AVDs
will mainly depend on the acceptable WTP threshold
that will be defined by German authorities on the basis
of the efficacy frontier approach. As there are no RP spe-
cific cost-effectiveness analyses available it is highly likely
that the ARMD cost-effectiveness thresholds will be ap-
plied which will result in a relatively high WTP threshold
located around €80,000 per QALY gained. Irrespective of
the discussions around the WTP threshold it needs to be
considered that a reimbursement decision of AVDs,
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outcomes of a cost-effectiveness assessment. Other, even
more important decision criteria, such as the innovative
nature of the AVD technology, the absence of effective
therapy methods in RP (high unmet medical need) as well
as the unprecedented therapy benefit (making the blind
see again) will be taken into account in order to decide on
the value and subsequently on the reimbursement of next
generation AVDs.
Current and future clinical and health economic evidence
requirements
The German reimbursement requirements for medical
devices are based on central regulating laws in the social
code book V that state that in the inpatient care setting
all (innovative) procedures are permitted with the reser-
vation of prohibition (German: Verbotsvorbehalt) [27]
and that in the outpatient care setting all (innovative)
procedures are prohibited until they have been officially
approved (German: Erlaubnisvorbehalt) [28]. This leads
to the case that medical devices applied in the German
inpatient setting require very limited clinical and health
economic evidence whereas strong clinical and health
economic evidence is required for medical devices ap-
plied in the German outpatient setting [29]. As AVDs
are implanted in an inpatient setting the clinical and
health economic evidence requirements are relatively
low but it is highly recommend to summarize all avail-
able evidence (clinical & health economic) in order to
support hospitals in the reimbursement fee negotiations
with the healthcare payers.
However, there are recent political and scientific streams
[30] that claim that the regulatory and reimbursement
process of medical devices should be adapted comparable
to the more restrictive regulations for pharmaceuticals,
which might have a major impact on the evidence require-
ments for the inpatient sector. In case that the medical de-
vice regulation would be aligned with the process for
pharmaceuticals, according to the act on the reform of the
market for medical products (German: Arzneimittelmarkt-
Neuordnungsgesetz; abbreviation: AMNOG) this would
mean that a detailed clinical and health economic evidence
reporting might be required to obtain reimbursement in
Germany, even for medical devices applied in the inpatient
setting.
Beside the possible changes of regulations, and a re-
lated possible increase of evidence requirements, there is
another key issue that inpatient medical devices are fa-
cing, which is related to the kind of health economic as-
sessments accepted by healthcare payers. The German
healthcare payers are used to focus on a short term per-
spective due to their yearly budget viewpoint and as a
consequence they consider short-term budget impact to
be more important than long-term cost-effectiveness.This fact is also reflected in the current AMNOG regu-
lations for pharmaceuticals that request only a short
term budget impact analysis but no (long-term) cost-
effectiveness assessment. This issue is of special import-
ance for implantable medical devices, such as next
generation AVDs, as a large part of the related costs are
generated in the year of implantation. These high first
year cost require that long term efficacy outcomes are
taken into account in order to obtain a cost-effective re-
lation between benefits and costs. Thus future regula-
tions on health economic evidence requirements need to
take into account these special characteristics of medical
devices and should therefore set the focus on (long-
term) cost-effectiveness and not on short-term budget
impact.
Conclusions
In conclusion the presented early cost-effectiveness
evaluation has obtained that next generation AVDs have
the potential to be a cost-effective therapy option in pa-
tients with RP in Germany. The innovative nature, the
high unmet medical need and the expected unprece-
dented efficacy of next generation AVDs will highly
likely lead to the case that even relatively high incremen-
tal cost-effectiveness ratios, that have been obtained
when simulating various effect and pricing scenarios,
will be regarded as acceptable from a German healthcare
payer perspective.
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